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Aim: Resistance patterns of Escherichia coli to fosfomycin, ciprofloxacin, amikacin, and cotrimoxazole were evaluated in 2 different
studies held in 2004 and 2005. In this study, it was aimed to compare the changes in the susceptibility patterns of uropathogenic E. coli
strains to the above-mentioned antibiotics after 6 years.
Materials and methods: Between February and April 2011, E. coli strains isolated from urine samples were included prospectively in
the study.
Results: A total of 502 E. coli strains (358 from outpatients and 144 from inpatients) were isolated from urine specimens between
February and April 2011. Extended spectrum beta-lactamase (ESBL)-producer E. coli rate was 35%. Resistances to cotrimoxazole,
ciprofloxacin, amikacin, and fosfomycin were 54.5%, 49.8%, 22.7%, and 1.4%, respectively. When we compared ESBL-producer E. coli
strains isolated in 2005 and 2011, amikacin resistance increased (11% to 22.7%, P = 0.0001), whereas cotrimoxazole resistance decreased
significantly (74% to 62.9%, P = 0.0063). When we compared resistance patterns of non-ESBL–producer E. coli in relation to 2004 and
2011, there was no significant change in the resistance to fosfomycin, cotrimoxazole, ciprofloxacin, and amikacin. Pooled analysis of
fosfomycin studies from Turkey revealed 1.6% fosfomycin resistance in a total of 6439 strains.
Conclusion: Our results suggest that despite common usage, there is not an increase in the resistance to fosfomycin. We conclude that
fosfomycin can be used as one of the primary choices in the empirical therapy of urinary tract infections.
Key words: Resistance, fosfomycin, urinary tract infection

1. Introduction
Community- and hospital-acquired urinary tract infections
(UTIs) are among the most frequently encountered
infectious diseases. According to the Turkish Statistical
Institute, UTIs were the third most common infection
in Turkey (the first being respiratory tract infections and
the second gastrointestinal infections) (1). Escherichia
coli is the most important bacterium that causes this
infection. Fosfomycin tromethamine (FT), trimethoprim/
sulfamethoxazole (cotrimoxazole), ciprofloxacin, and
amino glycosides are the most commonly preferred
antibacterial drugs for the treatment of communityacquired UTIs. Increasing antimicrobial resistance is a
major problem in bacteria isolated from both communityacquired and nosocomial UTIs. Extended spectrum
beta-lactamase (ESBL)-producing E. coli and Klebsiella
pneumoniae are major growing problems in almost every
country. Therefore, treatment options should be considered
* Correspondence: husnup@yahoo.com

due to the changing epidemiology and resistant rates.
The resistant rates of uropathogenic E. coli strains to
fosfomycin, ciprofloxacin, amikacin, and cotrimoxazole
were determined by 2 separate studies in our hospital
between 2004 and 2005 (2,3). We have also conducted
studies about fosfomycin use in complicated lower UTIs
caused by ESBL-producing E. coli (4,5). Fosfomycin usage
rates have increased, especially in the treatment of lower
UTIs, after detected low resistance rates against fosfomycin
in these studies. In our center, fosfomycin has been at the
forefront of empirical treatment in daily practice.
In this study, we aimed to evaluate the effect of
widespread use of fosfomycin in the treatment of UTIs on
antibiotic susceptibility patterns in the last 6 years.
2. Materials and methods
In February, March, and April 2011, mid-stream urine
samples that were collected in a sterile container were
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inoculated onto 5% sheep blood agar and eosin methylene
blue agar by using a quantitative method. The bacteria
were defined by conventional and automated methods
(API / VITEK 2, BioMérieux, Marcy-l’Étoile, France) in
samples in which bacterial growth was detected. Antibiotic
susceptibility to amikacin (30 µg), ciprofloxacin (5 µg),
trimethoprim-sulfamethoxazole (1.25/23.75 µg), and
fosfomycin (200 µg) was determined via disk diffusion tests
with antibiotic-containing disks (Oxoid Ltd., Basingstoke,
Hampshire, UK) on Mueller-Hinton agar plates. The
results were expressed as susceptible or resistant according
to criteria recommended by the Clinical and Laboratory
Standards Institute (CLSI) (6). ESBL production was
detected using the double disk synergy test.
E. coli ATCC 25922 was used as the control strain. Only
one isolate from each patient was included in the study;
recurrent isolates were excluded. Resistance patterns from
2004–2005 and 2011 were compared by chi-square test.
To find the published series of the last 5 years, 3 Turkish
national (ULAKBİM, http://www.turkishmedline.com,
and http://medline.pleksus.com.tr) and 2 international
(PubMed and Science Citation Index-Expanded) databases
were searched. Key words were “fosfomycin”, “Escherichia
coli”, “E. coli”, and “Turkey”. In cases of presentations from
a single study with intersecting periods, that covering a
longer period was chosen. Articles published before 2007
were excluded.
3. Results
A total of 502 E. coli isolates were included in the
study. Of the 502 E. coli isolates, 358 were isolated from
outpatients while 144 were isolated from inpatients. The
resistance rates were determined to be 1.4% for FT, 49.8%
for ciprofloxacin, 22.7% for amikacin, and 54.5% for
trimethoprim-sulfamethoxazole. ESBL-producing E. coli
strains were found in 35% of the isolates.
The resistance rates of ESBL-producing E. coli strains
in 2005 versus 2011 are summarized in Table 1. The
resistance rates of non-ESBL–producing E. coli strains in
2004 versus 2011 are shown in Table 2.
From 2005 to 2011, ESBL-producing E. coli strains
showed a significant rise in resistance to amikacin
(P = 0.0001) and a significant decline in resistance
to
trimethoprim/sulfamethoxazole
(cotrimoxazole)

(P = 0.0063), while no statistically significant difference
was observed in resistance to fosfomycin and ciprofloxacin.
For non-ESBL–producing E. coli strains, evaluation of
resistance rates from 2004 to 2011 revealed no significant
difference between data from 2005 and 2011 in terms of
resistance to fosfomycin, cotrimoxazole, ciprofloxacin,
and amikacin.
Of the past studies conducted in Turkey, including data
on resistance to fosfomycin, 10 studies were determined
to be eligible to be analyzed in the present study. Overall,
as summarized in Table 3, the average resistance rate of
the 6439 E. coli strains included in these studies was
determined to be 1.9% (resistance rate of 0.5% in nonESBL–producing E. coli strains and 5% in ESBL-producing
E. coli strains).
4. Discussion
UTIs are among the infectious diseases associated
with the most frequent use of antibiotics. Quinolones,
cotrimoxazole, amino glycosides, and nitrofurantoin (NFT)
are the first choices for the treatment of uncomplicated
UTIs. NFT is indicated in the treatment of uncomplicated
lower UTIs and is effective in vitro against E. coli strains,
including ESBL-producers. Resistance rates to NFT in
ESBL-negative and ESBL-producing E. coli were reported
to be 6.6% and 23.2%, respectively, from a tertiary care
educational hospital in Turkey (17,18). Sensitivity of strains
to NFT has not been investigated in this study. A recent
study from Turkey detected that the lowest resistance rates
of community-acquired E. coli strains were isolated from
urinary system infections for NFT (0.9%) and fosfomycin
(3.6%) (19). However, ever-increasing antibiotic resistance
of E. coli strains isolated from these infections together with
a particular rise in ESBL-producing strains in recent years
seriously challenges the treatment (13,14). The likelihood
of treatment failure with cotrimoxazole and quinolones
due to plasmid-mediated resistance renders carbapenems
as the primary therapeutic option (5,7). In this regard,
investigations continue in search of new antibiotics to
replace broad-spectrum, costly antibiotics like quinolones
that require hospitalization. Being recently introduced into
the market in Turkey, fosfomycin occupies a particularly
important place among these antibiotics given that high
concentrations were achieved in urine a short time after

Table 1. Resistance in ESBL-producing E. coli strains [n (%)].
Antibiotics

2005
(n = 344)

2011
(n = 178)

P-value

Ciprofloxacin (5 µg)

263 (76.4)

132 (74.1)

0.3359

Amikacin (30 µg)

38 (11.0)

62 (34.8)

0.0001

Cotrimoxazole (25 µg)

256 (74.4)

112 (62.9)

0.0063

12 (3.4)

4 (2.2)

0.4355

Fosfomycin (50 µg)
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Table 2. Resistance in non-ESBL–producing E. coli strains [n (%)].
Antibiotics

2004
(n = 72)

2011
(n = 324)

P-value

Ciprofloxacin (5 µg)

28 (39.0)

118 (36.4)

0.6945

Amikacin (30 µg)
Cotrimoxazole (25 µg)
Fosfomycin (50 µg)

5 (7.0)

53 (16.3)

0.0527

31 (43.0)

162 (50.0)

0.2863

0 (0.0)

3 (0.9)

0.4124

administration, along with low cost, low resistance rates,
and applicability without hospitalization (5,7).
The present study aimed to determine the influence
of more common usage of fosfomycin in UTIs during the
past 6 years and the alteration in sensitivity parameters
of antibiotics used as the first-line therapy of UTIs.
Comparison of E. coli strains isolated in 3 distinct time
points in terms of resistance rates in the present study
revealed a statistically significant increase in resistance
rates to amikacin and a decrease in resistance rates to
cotrimoxazole. There was no significant alteration in
resistance rates of other antibiotics evaluated.
Based on data from recent studies conducted in
Turkey, it is worth noting that amino glycosides still have
considerable priority in the empirical treatment of UTIs
(2,9,10,13,15). Likewise, in another study from our team,
pooled analysis of resistance rates of E. coli strains isolated
from UTIs revealed a high sensitivity to amino glycosides
with an average resistance rate of 6.1% to amikacin in a
total of 7960 E. coli strains derived from outpatients (20).
It seems likely that more frequent use of amikacin due to
low resistance rates determined in the recent period has a
role in the relative rise in resistance to drugs established
in 2011.
Ciprofloxacin is one of the most frequently
administered antibiotics in empirical approaches as
well as in causative agent-based treatment of UTIs.
However, rise in resistance rates to ciprofloxacin and
increasingly encountered ESBL-producing strains seem
to restrict the use of this antibiotic (5). Evaluation of past
studies published before 2007 revealed that resistance
to ciprofloxacin was 20.1% in a total of 15,221 E. coli
strains derived from outpatients (20). Resistance rates
in subsequent years have been reported to range from
27% to 69% (7,9,10,13). Notably, ESBL-producing E. coli
strains have been associated with higher resistance rates
to ciprofloxacin. Accordingly, the high resistance rates to
ciprofloxacin determined in the 3 periods in the present
study seem remarkable. Nevertheless, the likelihood of
microbiological eradication even in the resistant strains
should be taken into consideration for this drug given its
high urinary concentrations.

Cotrimoxazole has long been used as a safe treatment
in UTIs. However, high rates of resistance that developed
in relation to common use restrict the empirical use of
this agent. In a pooled analysis of 53 publications, the
resistance rate to cotrimoxazole was reported to be 47.1%
in a total of 17,533 E. coli strains derived from outpatients
(20). Resistance to cotrimoxazole was also determined to
be considerably high in the present study. Data from past
studies in Turkey indicate that resistance to cotrimoxazole
ranges from 47% to 72% (9,13). Hence, these high rates of
resistance support that the empirical use of this agent is
not reasonable.
In our previous study concerning antibiotics
frequently used in UTIs, no resistance to fosfomycin
was identified in 72 E. coli strains in 2004, while in
2005 the resistance rate to fosfomycin was reported to
be 3% in a total of 344 ESBL-producing E. coli strains.
Accordingly, empirical use of this agent in UTIs has
begun to gain wide currency. Administration of a single
dose of fosfomycin repeated every other day 3 times
was reported to be effective in patients with UTIs in
which the causative agent was an ESBL-producing E. coli
strain and the clinical picture was accompanied with no
systemic findings or complicating factors (4). Similarly,
fosfomycin (every other day, 1 × 1, 3 times) was reported
to be similar to meropenem (3 × 1/day, 14 days) in terms
of microbiological and clinical success in the treatment
of ESBL-producing E. coli strains related to complicated
lower UTI (5). Afterwards, this treatment protocol
became routinely applied at our hospital, particularly
in the infectious diseases, urology, physical therapy and
rehabilitation, and obstetrics and gynecology clinics.
Feedback on the administration of similar treatment
protocols has also been received from other centers in
Turkey. Fosfomycin has also been reported to be very
effective in the treatment of uncomplicated cystitis in
recent publications (12,21,22).
Resistance to fosfomycin was determined to be 1.4%
in 2011. Evaluation of subgroups revealed resistance to
fosfomycin in 12 of 344 ESBL-producing E. coli strains in
2005 while 4 of 178 ESBL-producing E. coli strains showed
resistance to fosfomycin in 2011, which may be related to
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Table 3. Resistance to fosfomycin: data from previous studies conducted in Turkey.
E. coli strains

Studies
Overall
number

Resistance
Non-ESBL–producing

ESBL-producing

Total

Investigator
(reference)

Year

Province

Yaşar et al. (7)

2011

İstanbul

416

7/312
(2.2)

5/104
(4.8)

12/416
(2.9)

Mengeloğlu et al. (8)

2011

Siirt

105

0/71
(0.0)

0/34
(0.0)

0/105
(0.0)

Bayram et al. (9)

2011

Van

375

13/263
(5.0)

17/112
(15.0)

30/375
(8.0)

Deveci et al. (10)

2010

Mardin

57

0/31
(0.0)

0/26
(0.0)

0/57
(0.0)

Ceran et al. (11)

2010

İstanbul

117

4/110
(3.6)

0/7
(0.0)

4/117
(3.4)

Hoşbul et al. (12)

2009

Ankara

771

0/621
(0.0)

3/150
(2.0)

3/771
(0.4)

Uyanık et al. (13)

2009

Erzurum

139

0/103
(0.0)

0/36
(0.0)

0/139
(0.0)

Aşık et al. (14)

2008

Afyon

80

–

1/80
(1.2)

1/80
(1.2)

Akyar et al. (15)

2007

İstanbul

1100

0/968
(0.0)

0/132
(0.0)

0/1100
(0.0)

Tekin et al. (16)

2006–2011

Diyarbakır

3279

0/2033
(0.0)

71/1246
(5.7)

71/3279
(2.2)

Total

2006–2012

Turkey

6439

24/4512
(0.5)

97/1927
(5.0)

121/6439
(1.9)

N

the limited number of cases and shorter time period in
2011. On the contrary, none of non-ESBL–producing E.
coli strains showed resistance to fosfomycin in 2004, while
resistance was determined in 3 non-ESBL–producing E.
coli strains in 2011. Two of these 3 strains were isolated
from bedridden patients who were undergoing 6-month
fosfomycin treatment due to recurrent UTIs. Data
from recently conducted studies in Turkey indicate low
resistance rates to fosfomycin in E. coli strains, with an
average resistance of 1.9% (range: 0%–15%) (7–16).
A limitation of this study seems to be the minor
differences in the included studies from 3 different periods.
While only community-acquired UTI cases were included
in the study conducted in 2004, resistance rates of ESBL-
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n/N (%)

producing E. coli strains were determined regardless of
the discrimination of community- or hospital-acquired
infection in 2005. Moreover, data from 2011 included
evaluation of strains with respect to outpatient versus
inpatient origin. Nevertheless, despite these differences, all
3 studies provide substantial data considering resistance
rates specific to our region.
Data from the studies about fosfomycin cover
a relatively long period of time, starting from the
introduction of fosfomycin in clinical practice in the early
1970s. The studies have not shown a major difference in the
susceptibility to fosfomycin between the first and the last
year of the study period (23). In conclusion, our findings
revealed no increase in resistance rates to fosfomycin

PULLUKÇU et al. / Turk J Med Sci
despite its more common use in UTIs for the past 6 years
as well as no significant differences in resistance rates to
other antibiotics. Accordingly, fosfomycin seems to be a

safe remedy that continues to hold its ranking among the
first treatment choices of both empirical and causative
agent-based treatment of UTIs.
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